NCT07122895View on ClinicalTrials.gov

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

March 31, 2030

Conditions
Schizophrenia
Interventions
DRUG

NMDAE

Use of an NMDA enhancer for the treatment of negative symptoms

DRUG

Placebo Cap

Use of placebo as a comparator

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

lead

China Medical University Hospital

OTHER

NCT07122895 - Sex Differences in NMDA-enhancing Treatment of Schizophrenia | Biotech Hunter | Biotech Hunter